{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:33:04Z","timestamp":1789162384935,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10067-023-06826-y","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T05:01:41Z","timestamp":1700888501000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CXCL9 and NT-proBNP, a notable link between inflammatory mediator and cardiovascular disease biomarker in rheumatoid arthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-2381","authenticated-orcid":false,"given":"Afsaneh","family":"Shamsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-0653","authenticated-orcid":false,"given":"Seyed Askar","family":"Roghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5517-791X","authenticated-orcid":false,"given":"Parviz","family":"Soufivand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-3049","authenticated-orcid":false,"given":"Mehran","family":"Pournazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3012-0168","authenticated-orcid":false,"given":"Fatemeh","family":"Khoobbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-6847","authenticated-orcid":false,"given":"Fariborz","family":"Bahrehmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-0130","authenticated-orcid":false,"given":"Mahdi","family":"Taghadosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"issue":"6","key":"6826_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese EM, Firestein GS (2023) Rheumatoid arthritis\u2014common origins, divergent mechanisms. N Engl J Med 388(6):529\u2013542","journal-title":"N Engl J Med"},{"issue":"4","key":"6826_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"Y-J Lin","year":"2020","unstructured":"Lin Y-J, Anzaghe M, Sch\u00fclke S (2020) Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells 9(4):880","journal-title":"Cells"},{"issue":"5","key":"6826_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K et al (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41(5):863\u2013877","journal-title":"Rheumatol Int"},{"issue":"7","key":"6826_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","volume":"16","author":"AG Semb","year":"2020","unstructured":"Semb AG et al (2020) Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol 16(7):361\u2013379","journal-title":"Nat Rev Rheumatol"},{"key":"6826_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40744-019-00189-0","volume":"7","author":"DJ DeMizio","year":"2020","unstructured":"DeMizio DJ, Geraldino-Pardilla LB (2020) Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatology and therapy 7:19\u201333","journal-title":"Rheumatology and therapy"},{"issue":"4","key":"6826_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776","volume":"20","author":"FA Figus","year":"2021","unstructured":"Figus FA et al (2021) Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev 20(4):102776","journal-title":"Autoimmun Rev"},{"key":"6826_CR7","doi-asserted-by":"crossref","unstructured":"Fazeli MS et al (2021) Cardiovascular disease in rheumatoid arthritis: risk factors, autoantibodies, and the effect of antirheumatic therapies. Clin Med Insights: Arthritis Musculoskelet Disord 14:1179544121102875","DOI":"10.1177\/11795441211028751"},{"issue":"10","key":"6826_CR8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/life11101042","volume":"11","author":"E Rezu\u015f","year":"2021","unstructured":"Rezu\u015f E et al (2021) Ischemic heart disease and rheumatoid arthritis\u2014two conditions, the same background. Life 11(10):1042","journal-title":"Life"},{"issue":"1","key":"6826_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001032","volume":"6","author":"P B\u0142yszczuk","year":"2020","unstructured":"B\u0142yszczuk P, Szekanecz Z (2020) Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open 6(1):e001032","journal-title":"RMD Open"},{"key":"6826_CR10","unstructured":"Khatnawliya S et al (2020) A study of the cardiac manifestations in rheumatoid arthritis patients with special reference to echocardiography. J Indian Acad Clin Med 21(3\u20134)"},{"key":"6826_CR11","doi-asserted-by":"crossref","unstructured":"Johnson T (2022) Cytokines and chemokines are associated with the risk of cardiovascular disease in rheumatoid arthritis independent of conventional disease activity measures. Cytokines 4(1)","DOI":"10.32873\/unmc.dc.gmerj.4.1.021"},{"issue":"4","key":"6826_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/ATVBAHA.118.312037","volume":"39","author":"H Noels","year":"2019","unstructured":"Noels H, Weber C, Koenen RR (2019) Chemokines as therapeutic targets in cardiovascular disease: the road behind, the road ahead. Arterioscler Thromb Vasc Biol 39(4):583\u2013592","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"6826_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","volume":"15","author":"LD Ferguson","year":"2019","unstructured":"Ferguson LD et al (2019) Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol 15(8):461\u2013474","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"6826_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43587-021-00082-y","volume":"1","author":"N Sayed","year":"2021","unstructured":"Sayed N et al (2021) An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nature aging 1(7):598\u2013615","journal-title":"Nature aging"},{"key":"6826_CR15","doi-asserted-by":"crossref","unstructured":"Lu X et al (2022) The role of CXC chemokines in cardiovascular diseases. Front Pharmacol 12:765768","DOI":"10.3389\/fphar.2021.765768"},{"issue":"6","key":"6826_CR16","first-page":"e472","volume":"170","author":"S Paparo","year":"2019","unstructured":"Paparo S (2019) Rheumatoid arthritis and the Th1 chemokine MIG. Clin Ter 170(6):e472-477","journal-title":"Clin Ter"},{"key":"6826_CR17","doi-asserted-by":"crossref","unstructured":"Hannawi S, Hannawi H, Al Salmi I (2020) Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis. Hypertens Res 43(9): 982\u2013984","DOI":"10.1038\/s41440-020-0483-4"},{"issue":"1","key":"6826_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/diagnostics12010182","volume":"12","author":"B Frade-Sosa","year":"2022","unstructured":"Frade-Sosa B et al (2022) High sensitivity c reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or Jak inhibitors: a clinical and ultrasonographic study. Diagnostics 12(1):182","journal-title":"Diagnostics"},{"key":"6826_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ (2018) Role of C-reactive protein at sites of inflammation and infection. Front Immunol 9:754","journal-title":"Front Immunol"},{"key":"6826_CR20","doi-asserted-by":"crossref","unstructured":"Pope JE, Choy EH (2021) C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheumatism 51(1):219\u2013229","DOI":"10.1016\/j.semarthrit.2020.11.005"},{"issue":"7","key":"6826_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006242","volume":"4","author":"J Graf","year":"2009","unstructured":"Graf J et al (2009) Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS ONE 4(7):e6242","journal-title":"PLoS ONE"},{"issue":"3","key":"6826_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1541-9215.2003.02109.x","volume":"1","author":"JL Torres","year":"2003","unstructured":"Torres JL, Ridker PM (2003) High sensitivity C-reactive protein in clinical practice. Am Heart Hosp J 1(3):207\u2013211","journal-title":"Am Heart Hosp J"},{"key":"6826_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100553","volume":"29","author":"H Rudolf","year":"2020","unstructured":"Rudolf H et al (2020) NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: the getABI-study. IJC Heart Vasc 29:100553","journal-title":"IJC Heart Vasc"},{"issue":"4","key":"6826_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026030","volume":"9","author":"E-H Nah","year":"2019","unstructured":"Nah E-H et al (2019) Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study. BMJ Open 9(4):e026030","journal-title":"BMJ Open"},{"issue":"1","key":"6826_CR25","doi-asserted-by":"publisher","first-page":"13088","DOI":"10.1038\/s41598-021-92488-2","volume":"11","author":"FG Bellagambi","year":"2021","unstructured":"Bellagambi FG et al (2021) Determination and stability of N-terminal pro-brain natriuretic peptide in saliva samples for monitoring heart failure. Sci Rep 11(1):13088","journal-title":"Sci Rep"},{"issue":"2","key":"6826_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3899\/jrheum.090769","volume":"37","author":"WP Kuan","year":"2010","unstructured":"Kuan WP et al (2010) CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 37(2):257\u2013264","journal-title":"J Rheumatol"},{"issue":"1","key":"6826_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1224-1","volume":"19","author":"JM Pandya","year":"2017","unstructured":"Pandya JM et al (2017) Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res Ther 19(1):1\u201312","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6826_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.aller.2013.11.003","volume":"43","author":"AK Shrivastava","year":"2015","unstructured":"Shrivastava AK et al (2015) Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol 43(1):81\u201387","journal-title":"Allergol Immunopathol"},{"issue":"6","key":"6826_CR29","first-page":"1095","volume":"31","author":"PH Dessein","year":"2004","unstructured":"Dessein PH, Joffe BI, Stanwix AE (2004) High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 31(6):1095\u20131097","journal-title":"J Rheumatol"},{"issue":"1","key":"6826_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","volume":"51","author":"JE Pope","year":"2021","unstructured":"Pope JE, Choy EH (2021) C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 51(1):219\u2013229","journal-title":"Semin Arthritis Rheum"},{"key":"6826_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2017.02.003","volume":"259","author":"Y Li","year":"2017","unstructured":"Li Y et al (2017) Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis 259:75\u201382","journal-title":"Atherosclerosis"},{"key":"6826_CR32","doi-asserted-by":"crossref","unstructured":"Kay J, Upchurch KS (2012) ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(suppl_6):vi5\u2013vi9","DOI":"10.1093\/rheumatology\/kes279"},{"issue":"9","key":"6826_CR33","first-page":"409","volume":"105","author":"MB Clearfield","year":"2005","unstructured":"Clearfield MB (2005) C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 105(9):409\u2013416","journal-title":"J Am Osteopath Assoc"},{"issue":"1","key":"6826_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/clc.23760","volume":"45","author":"X Zhao","year":"2022","unstructured":"Zhao X et al (2022) NT Pro-BNP can be used as a risk predictor of clinical atrial fibrillation with or without left atrial enlargement. Clin Cardiol 45(1):68\u201374","journal-title":"Clin Cardiol"},{"issue":"4","key":"6826_CR35","doi-asserted-by":"publisher","first-page":"A257","DOI":"10.1016\/j.chest.2021.07.265","volume":"160","author":"L Kondrateva","year":"2021","unstructured":"Kondrateva L et al (2021) N-terminal pro-brain natriuretic peptide levels in patients with early and long-term rheumatoid arthritis. Chest 160(4):A257","journal-title":"Chest"},{"issue":"5","key":"6826_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17116\/terarkh201688519-26","volume":"88","author":"I Kirillova","year":"2016","unstructured":"Kirillova I et al (2016) N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs. Ter Arkh 88(5):19\u201326","journal-title":"Ter Arkh"},{"issue":"6","key":"6826_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253793","volume":"16","author":"TH Nguyen","year":"2021","unstructured":"Nguyen TH et al (2021) Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. PLoS ONE 16(6):e0253793","journal-title":"PLoS ONE"},{"key":"6826_CR38","doi-asserted-by":"crossref","unstructured":"Novikova D et al (2019) P4434The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up. Eur Heart J 40(Supplement_1)","DOI":"10.1093\/eurheartj\/ehz745.0836"},{"issue":"Suppl 2","key":"6826_CR39","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/annrheumdis-2016-eular.4903","volume":"75","author":"IG Kirillova","year":"2016","unstructured":"Kirillova IG et al (2016) SAT0113 implementation of the treat-to-target strategy leads to dramatically reduction of n-terminal pro-brain natriuretic peptide level in patients with early rheumatoid arthritis. Ann Rheum Dis 75(Suppl 2):706\u2013706","journal-title":"Ann Rheum Dis"},{"key":"6826_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10067-017-3961-6","volume":"37","author":"GA Rongen","year":"2018","unstructured":"Rongen GA et al (2018) Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin Rheumatol 37:909\u2013916","journal-title":"Clin Rheumatol"},{"key":"6826_CR41","doi-asserted-by":"crossref","unstructured":"Mezzasoma L, Antognelli C, Talesa VN (2017) A novel role for brain natriuretic peptide: inhibition of IL-1\u03b2 secretion via downregulation of NF-kB\/Erk 1\/2 and NALP3\/ASC\/Caspase-1 activation in human THP-1 monocyte. Mediat Inflamm 2017","DOI":"10.1155\/2017\/5858315"},{"key":"6826_CR42","doi-asserted-by":"crossref","unstructured":"Shamsi, A et al (2023) CXCL9 and its receptor CXCR3, an important link between inflammation and cardiovascular risks in RA patients","DOI":"10.21203\/rs.3.rs-2868920\/v1"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06826-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:13:13Z","timestamp":1704690793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6826"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06826-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}